ASX:PAR Paradigm Biopharmaceuticals (PAR) Stock Price, News & Analysis → How this is some devastating news (From WealthPress) (Ad) Free PAR Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume1.81 million shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Paradigm Biopharmaceuticals alerts: Email Address Ad Allegiance GoldDoes this make you sick?The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments.Get your Free Wealth Protection Kit About Paradigm Biopharmaceuticals Stock (ASX:PAR)Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.Read More Ad Allegiance GoldDoes this make you sick?The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments.Get your Free Wealth Protection Kit PAR Stock News HeadlinesMay 16, 2024 | tmcnet.comParadigm by Puloli™ to Keynote and Sponsor Major Industry EventsMay 9, 2024 | msn.comParadigm Hires Craig Bernstein, Lindsay Samakow To Launch Physical Production, Speakers DepartmentsMay 9, 2024 | msn.comBell Potter says this ASX biotech stock could rocket 80%May 2, 2024 | finance.yahoo.comReunion Neuroscience Inc. Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo HoldingsApril 30, 2024 | msn.comLimited-edition Skydeck Residences at Alaya by Paradigm Realty and Prozone give home buyers their own slice of sky in the heart of MumbaiApril 30, 2024 | msn.com3 ASX healthcare shares outperforming on quarterly updatesApril 29, 2024 | markets.businessinsider.comGeorge Medicines Appoints Mark Mallon as Chief Executive Officer and Board DirectorApril 26, 2024 | finance.yahoo.comPhaseV and Quanticate Partner to Enable Clinical Trial Sponsors to Improve Recruitment, Time to Market and Quality of StudiesApril 24, 2024 | finance.yahoo.comBicycle Therapeutics Announces Two Abstracts Accepted for Presentation at the 2024 ASCO Annual MeetingApril 19, 2024 | msn.comParadigm Signs ‘Fire Island’ & ‘How To Get Away With Murder’ Actor Conrad RicamoraApril 19, 2024 | msn.comParadigm makes key submission to US FDA to advance osteoarthritis Phase 3 trialApril 17, 2024 | msn.comSheboygan jazz masterclass at Paradigm will feature Milwaukee Jazz Institute's managing directorApril 9, 2024 | msn.comWWE Star Damian Priest Signs With Paradigm (EXCLUSIVE)April 9, 2024 | benzinga.comMonad Labs Raises $225 Million in Funding Round Led by ParadigmApril 9, 2024 | sg.style.yahoo.com10 best makan places in Paradigm Mall JBApril 4, 2024 | msn.comReggie Bush Signs With Paradigm Talent Agency In All Areas, Launches Production CompanyApril 2, 2024 | msn.comMerkle Achieves $1 Billion Valuation with Paradigm Leading Funding SurgeMarch 27, 2024 | msn.comParadigm Signs ‘Red, White & Royal Blue’ Breakout Taylor Zakhar PerezMarch 20, 2024 | msn.comLit Agents Alysia Thomas, Kelsey Roberts Exit ParadigmMarch 19, 2024 | uk.movies.yahoo.comParadigm Hires Verve Alums Bill Weinstein, Devon Schiff As Lit AgentsMarch 19, 2024 | msn.comBill Weinstein Joins Paradigm Talent Agency Following Verve ExitMarch 19, 2024 | msn.comBill Weinstein & Paradigm At The Altar? – The DishMarch 18, 2024 | msn.comOcugen's Revolutionary Gene Therapy Targets Geographic Atrophy: A Shift in Ophthalmology on the HorizonMarch 13, 2024 | finance.yahoo.comShift Paradigm acquires design and technology consultancy Principle StudiosMarch 11, 2024 | msn.comMonad Labs in talks to raise more than $200 million round led by Paradigm, valuing the Jump Crypto–linked startup at $3 billionSee More Headlines Receive PAR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Paradigm Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:PAR CUSIPN/A CIKN/A Webwww.paradigmbiopharma.com Phone61 3 9629 5566FaxN/AEmployees1,031Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-69,000,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-128.42% Return on Assets-72.47% Debt Debt-to-Equity Ratio0.86 Current Ratio3.83 Quick Ratio5.93 Sales & Book Value Annual Sales$79,224.00 Price / Sales0.00 Cash FlowN/A Price / Cash Flow6.44 Book ValueA$0.10 per share Price / BookN/AMiscellaneous Outstanding Shares350,360,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta1.00 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Paul John Rennie BSc (Age 65)Grad Dip, MBM, MSTC, Founder, MD & Executive Chairman Comp: $1.75MDr. Donna L. Skerrett M.D. (Age 67)MS, Chief Medical Officer and Executive Director Comp: $1.26MMs. Abby Macnish Niven B.Com.B.Sc., C.F.A., Interim Company Secretary & Interim CFODr. Ravi KrishnanChief Scientific OfficerMr. Simon WhiteDirector of Investor RelationsDr. Michael ImperialeGlobal Head of Drug Safety & MPSMs. Beverley HuttmannCommercial HeadMs. Michelle CoffeyGlobal Head of Regulatory AffairsDr. Mukesh AhujaGlobal Clinical Head of OAMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All CompetitorsInsidersPaul RennieSold 349,500 sharesTotal: $136,305.00 ($0.39/share) PAR Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Paradigm Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Paradigm Biopharmaceuticals investors own include BHP Group (BHP), Electro Optic Systems (EOS), First Graphene (FGR), Envirosuite (EVS), Bubs Australia (BUB), Blue Energy (BLU), BHP Group (BHP), Alcidion Group (ALC), a2 Milk (A2M) and 8common (8CO). This page (ASX:PAR) was last updated on 5/21/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsDoes this make you sick?Allegiance Gold[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 Media4 Cryptos BETTER than BitcoinTrue Market InsidersBill Gates is all about this tiny $2 stockTimothy SykesThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldBill Clinton Backing Biden Replacement???The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Paradigm Biopharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.